Ataxia-telangiectasia (A-T) is a rare autosomal recessive neurodegenerative disorder caused by mutations in the ATM (ataxia-telangiectasia mutated) gene. Cerebellar granule cells are particularly vulnerable to ATM deficiency, leading to progressive cerebellar degeneration and ataxia. Understanding the molecular mechanisms of granule cell vulnerability in A-T provides insights into DNA damage responses, oxidative stress, and potential therapeutic strategies for broader neurodegenerative contexts.
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000120 | granule cell |
The ATM gene encodes a serine/threonine protein kinase central to DNA damage response:
| Feature | Details |
|---|---|
| Gene location | Chromosome 11q22-23 |
| Protein | ATM kinase (350 kDa) |
| Function | DNA double-strand break repair |
| Inheritance | Autosomal recessive |
| Mutation types | Nonsense, missense, frameshift, splicing |
| System | Manifestation | Mechanism |
|---|---|---|
| Neurological | Cerebellar ataxia | Granule/Purkinje cell loss |
| Immunological | Recurrent infections | T/B cell deficiency |
| Cutaneous | Telangiectasias | Vascular fragility |
| Endocrine | Diabetes, growth delay | ATM in metabolic tissues |
| Oncological | Cancer predisposition | Genomic instability |
Cerebellar granule cells exhibit unique susceptibility to ATM deficiency:
| Property | Description |
|---|---|
| Number | Most abundant neurons in brain (~10^11) |
| Location | Cerebellar granular layer |
| Input | Mossy fibers |
| Output | Parallel fibers to molecular layer |
| Neurotransmitter | Glutamate |
| Target | Purkinje cell dendrites |
Neurons accumulate DNA damage throughout life due to:
| Step | ATM Target | Function |
|---|---|---|
| Detection | MRN complex | DSB sensing |
| Signaling | ATM autophosphorylation | Kinase activation |
| Chromatin | H2AX (γ-H2AX) | Damage marking |
| Cell cycle | p53, CHK2 | Cell cycle arrest |
| Repair | BRCA1, NBS1 | Homologous recombination |
Without functional ATM:
| Target | Damage Type | Consequence |
|---|---|---|
| DNA | 8-oxo-guanine | Mutations |
| Lipids | Lipid peroxidation | Membrane dysfunction |
| Proteins | Carbonylation | Protein aggregation |
| Mitochondria | mtDNA damage | ETC dysfunction |
A-T shows characteristic cerebellar changes:
| Cell Type | A-T Changes |
|---|---|
| Granule cells | Marked loss, especially vermis |
| Purkinje cells | Dendritic atrophy, reduced density |
| Basket cells | Relatively preserved |
| Golgi cells | Variable loss |
| Molecular layer | Thinned |
| Feature | Age of Onset | Progression |
|---|---|---|
| Gait ataxia | 1-2 years | Progressive |
| Dysarthria | 3-5 years | Slowly progressive |
| Oculomotor apraxia | 2-4 years | Persistent |
| Choreoathetosis | 5-10 years | Variable |
| Peripheral neuropathy | Teens | Progressive |
| Intervention | Target | Evidence |
|---|---|---|
| Physical therapy | Motor function | Symptomatic benefit |
| Speech therapy | Communication | Supportive |
| Immunoglobulin | Infection prevention | Reduced infections |
| Antioxidants | Oxidative stress | Limited evidence |
| Approach | Mechanism | Status |
|---|---|---|
| Read-through compounds | Nonsense mutation bypass | Preclinical |
| ATMi inhibitors | Modulate ATM pathway | Research |
| Neuroprotective agents | Reduce granule cell death | Clinical trials |
| Stem cell therapy | Replace lost cells | Early research |
A-T provides insights into:
| Disorder | Shared Features |
|---|---|
| Alzheimer disease | Oxidative stress, DNA damage |
| Parkinson disease | Mitochondrial dysfunction |
| ALS | Impaired DNA repair |
| Spinocerebellar ataxias | Cerebellar degeneration |
MRI cerebellum: Progressive atrophy
Vermis: Early involvement
Cerebral white matter: Variable changes
Spinal cord: Occasional atrophy
Neurons Major brain cell type
Glia — Suppor- Alzheimer's DiseaseAlzhe- Parkinson's Diseased neurodegenerative disease
Parkinson's Disease Related neurodegenerative disease